Delayed drug hypersensitivity reactions and associated factors in inpatients at the National Hospital of Dermatology and Venereology
Main Article Content
Abstract
This retrospective cross-sectional study aimed to analyze the clinical patterns and associated factors of delayed drug hypersensitivity reactions (DHRs) among inpatients at the National Hospital of Dermatology and Venereology from January 2019 to December 2023. A total of 266 medical records were reviewed, revealing that DHRs presented with a wide spectrum of clinical manifestations, ranging from mild to severe. Cases occurred across all age groups, with a higher proportion of severe forms observed in the elderly. The distribution between males and females was relatively equal. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) were the most common manifestations, accounting for 26.7% and 22.2% of cases, respectively, while overlap SJS/TEN was the least common (1.1%). The oral route was the most frequent mode of drug administration associated with DHRs. There was no statistically significant association between the route of administration and the onset time of symptoms (p > 0.05). Multiple drug classes were implicated, with antibiotics and traditional herbal medicines (including Eastern and Vietnamese folk remedies) being the most common culprits. Notably, half of the patients had at least one underlying comorbidity.
Article Details
Keywords
delayed drug hypersensitivity, cutaneous adverse drug reactions
References
2. Yx T, Sa W. Severe adverse drug reactions. Clin Med Lond Engl. 2016;16(1). doi:10.7861/clinmedicine.16-1-79
3. Suástegui-Rodríguez I, Campos-Jiménez KI, Domínguez-Cherit J, et al. Adverse cutaneous reactions to drugs. Rev Medica Inst Mex Seguro Soc. 2018;56(1):64-70.
4. Gomes ESR, Marques ML, Regateiro FS. Epidemiology and Risk Factors for Severe Delayed Drug Hypersensitivity Reactions. Curr Pharm Des. 2019;25(36):3799-3812. doi:10.2174/1381612825666191105115346
5. Tissot M, Valnet-Rabier MB, Stalder T, et al. Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance data. Therapies. 2022;77(3):291-300. doi:10.1016/j.therap.2021.12.007
6. Trần Thị Phương Chi, Hoàng Thị Lâm. Nghiên cứu tình trạng dị ứng thuốc tại bệnh viện Đà Nẵng. Tạp chí Y học Việt Nam. 2022;521(Số 2):307.
7. Nguyễn Văn Đoàn, Nguyễn Năng An. Kết quả nghiên cứu dị ứng thuốc tại Khoa Dị ứng - MDLS Bệnh viện Bạch Mai (1981-2005). Tạp chí Y học lâm sàng Bệnh viện Bạch Mai. 2006;Số đặc san:79-89.
8. Lekshmipriya K, Pradeesh A, Vasudevan B, et al. An observational study of severe cutaneous adverse reactions at a tertiary care teaching hospital. Med J Armed Forces India. 2023;79(Suppl 1):S209-S216. doi:10.1016/j.mjafi.2022.06.011
9. Deng M, Su Y, Wu R, et al. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China. Int Immunopharmacol. 2023;114:109530. doi:10.1016/j.intimp.2022.109530
10. AlJasser MI. Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia. Dermatol Res Pract. 2023;2023:8928198. doi:10.1155/2023/8928198
11. Sinha S, Kar C, Das S, et al. A Clinico-Epidemiological Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Centre of Eastern India. Indian J Dermatol. 2024;69(1):106. doi:10.4103/ijd.ijd_944_20
12. Zheng L, Jin HB, Guan YY, et al. Pharmacovigilance of cutaneous adverse drug reactions in associations with drugs and medical conditions: a retrospective study of hospitalized patients. BMC Pharmacol Toxicol. 2022;23(1):62. doi:10.1186/s40360-022-00603-4
13. Zhao J, Hu L, Zhang L, et al. Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis. An Bras Dermatol. 2019;94(6):664-670. doi:10.1016/j.abd.2019.01.007
14. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India. J Postgrad Med. 2001;47(2):95-99.